FDA Grants Fast Track Designation to AKY-1189 for Urothelial Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy AKTS?
Source: Newsfilter
- FDA Fast Track Designation: The U.S. FDA has granted Fast Track designation to AKY-1189 for the treatment of locally advanced or metastatic urothelial cancer, aimed at expediting the development and review process to address this unmet medical need.
- Clinical Trial Progress: Aktis is conducting a multi-site Phase 1b clinical trial involving various tumor types, including locally advanced or metastatic urothelial cancer, with preliminary results expected in Q1 2027, further validating the efficacy of AKY-1189.
- Targeted Treatment Potential: AKY-1189 utilizes Aktis' miniprotein radioconjugate platform to specifically target Nectin-4 expressing tumors, with approximately 80-90% of urothelial cancer patients showing positive Nectin-4 expression, indicating broad applicability.
- Strategic Collaboration Opportunities: Aktis has established a strategic collaboration with Eli Lilly to leverage its miniprotein platform for developing novel radioconjugates, further expanding the indications for AKY-1189 and enhancing the company's market competitiveness in oncology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AKTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AKTS
Wall Street analysts forecast AKTS stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.130
Low
30.00
Averages
31.67
High
34.00
Current: 20.130
Low
30.00
Averages
31.67
High
34.00
About AKTS
Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Grants Fast Track Designation to AKY-1189 for Urothelial Cancer Treatment
- FDA Fast Track Designation: The U.S. FDA has granted Fast Track designation to AKY-1189 for the treatment of locally advanced or metastatic urothelial cancer, aimed at expediting the development and review process to address this unmet medical need.
- Clinical Trial Progress: Aktis is conducting a multi-site Phase 1b clinical trial involving various tumor types, including locally advanced or metastatic urothelial cancer, with preliminary results expected in Q1 2027, further validating the efficacy of AKY-1189.
- Targeted Treatment Potential: AKY-1189 utilizes Aktis' miniprotein radioconjugate platform to specifically target Nectin-4 expressing tumors, with approximately 80-90% of urothelial cancer patients showing positive Nectin-4 expression, indicating broad applicability.
- Strategic Collaboration Opportunities: Aktis has established a strategic collaboration with Eli Lilly to leverage its miniprotein platform for developing novel radioconjugates, further expanding the indications for AKY-1189 and enhancing the company's market competitiveness in oncology.
See More
2026 IPO Market Starts Steadily with $2.6 Billion Raised
- IPO Market Performance: In January 2026, nine IPOs raised a total of $2.6 billion, although a backlog of startups indicated IPO plans, the overall deal count and proceeds fell below the ten-year average, reflecting cautious market sentiment.
- Sector Dynamics: The industrial sector's EquipmentShare.com led with $747 million raised, surging 33% on its first day, indicating strong investor demand for fast-growing companies viewed as resistant to AI disruption.
- SPAC Issuance Surge: January saw SPAC issuance reach a four-year high with 25 blank check deals raising $5.2 billion, providing hundreds of pre-IPO companies with an alternative path to public markets, reflecting growing interest in emerging technology firms.
- Active IPO Pipeline: By the end of January, the IPO pipeline included 216 companies seeking to raise approximately $12.4 billion, with 130 having filed or updated within the last 90 days, demonstrating ongoing market interest in new public offerings.
See More
2026 IPO Market Starts Steadily with $2.6 Billion Raised
- IPO Market Performance: In January 2026, nine IPOs raised a total of $2.6 billion, reflecting a cautious market sentiment as this figure fell short of the ten-year average, particularly after the volatility experienced in Q4 2025.
- Sector Dynamics: The industrial sector led the month’s largest IPOs, with EquipmentShare.com raising $747 million, highlighting investor preference for fast-growing companies perceived as resilient to AI disruption.
- Emerging Trends: The fintech and biotech sectors showed signs of recovery at the start of 2026, notably with fintech PicPay becoming the first Brazilian IPO in four years, raising $434 million, although its shares fell 5% post-IPO.
- SPAC Activity: January saw SPAC issuance reach a four-year high with 25 deals raising $5.2 billion, indicating growing interest in pre-IPO companies opting for SPAC mergers, despite overall IPO activity remaining below 2021 peaks.
See More
Wall Street Analysts Adjust Ratings
- Rating Changes Overview: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market perspectives and expectations for these companies.
- Market Impact Analysis: The changes in analysts' ratings could influence investor decisions, particularly for those considering buying GLIBK stock, as these adjustments convey important market signals.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing a comprehensive market perspective and data support.
- Investment Advice Reminder: Benzinga emphasizes that it does not provide investment advice, urging investors to carefully consider analysts' ratings and market dynamics before making decisions.
See More
Helen Kim Acquires 835,000 Shares of AKTS for $15.03M Investment
- Large Transaction: Helen Susan Kim purchased 835,000 shares of AKTS on Monday at $18 each, totaling a $15.03 million investment, marking her first stock purchase in the past 12 months and indicating confidence in the company's future prospects.
- Price Fluctuation: On Tuesday, AKTS reached a high of $23.50, with Kim's investment up approximately 30.6% at the peak, reflecting a positive market response that may attract further investor interest.
- Market Performance: Aktis Oncology Inc saw a 1.8% increase in stock price on Tuesday, indicating a favorable market reaction to Kim's purchase, which could further stabilize the company's stock growth.
- Another Transaction: On the same day, Carl J. Rickertsen bought 5,000 shares of Strategy at $155.88 each, totaling $779,395, marking his first purchase in the past 12 months and demonstrating optimism towards the company.
See More
Aktis Oncology Closes Upsized IPO Raising $365.4 Million
- Successful IPO: Aktis Oncology completed its initial public offering of 17.65 million shares on January 12, 2026, at an IPO price of $18 per share, indicating strong market demand for its targeted radiopharmaceuticals.
- Additional Share Purchase: Underwriters fully exercised their option to purchase an additional 2.6475 million shares, expected to close on January 14, 2026, further strengthening the company's financial position to support R&D and market expansion.
- Significant Fundraising: The total gross proceeds from the offering are expected to reach approximately $365.4 million, reflecting investor confidence in Aktis's innovative potential in cancer treatment and providing ample funding for future product development.
- Strong Market Debut: Aktis's stock began trading on the Nasdaq Global Select Market on January 9, 2026, under the ticker symbol “AKTS,” marking a successful entry into the capital markets and likely enhancing its brand visibility and competitive position.
See More
FDA Grants Fast Track Designation to AKY-1189 for Urothelial Cancer Treatment
- FDA Fast Track Designation: The U.S. FDA has granted Fast Track designation to AKY-1189 for the treatment of locally advanced or metastatic urothelial cancer, aimed at expediting the development and review process to address this unmet medical need.
- Clinical Trial Progress: Aktis is conducting a multi-site Phase 1b clinical trial involving various tumor types, including locally advanced or metastatic urothelial cancer, with preliminary results expected in Q1 2027, further validating the efficacy of AKY-1189.
- Targeted Treatment Potential: AKY-1189 utilizes Aktis' miniprotein radioconjugate platform to specifically target Nectin-4 expressing tumors, with approximately 80-90% of urothelial cancer patients showing positive Nectin-4 expression, indicating broad applicability.
- Strategic Collaboration Opportunities: Aktis has established a strategic collaboration with Eli Lilly to leverage its miniprotein platform for developing novel radioconjugates, further expanding the indications for AKY-1189 and enhancing the company's market competitiveness in oncology.
See More
2026 IPO Market Starts Steadily with $2.6 Billion Raised
- IPO Market Performance: In January 2026, nine IPOs raised a total of $2.6 billion, although a backlog of startups indicated IPO plans, the overall deal count and proceeds fell below the ten-year average, reflecting cautious market sentiment.
- Sector Dynamics: The industrial sector's EquipmentShare.com led with $747 million raised, surging 33% on its first day, indicating strong investor demand for fast-growing companies viewed as resistant to AI disruption.
- SPAC Issuance Surge: January saw SPAC issuance reach a four-year high with 25 blank check deals raising $5.2 billion, providing hundreds of pre-IPO companies with an alternative path to public markets, reflecting growing interest in emerging technology firms.
- Active IPO Pipeline: By the end of January, the IPO pipeline included 216 companies seeking to raise approximately $12.4 billion, with 130 having filed or updated within the last 90 days, demonstrating ongoing market interest in new public offerings.
See More
2026 IPO Market Starts Steadily with $2.6 Billion Raised
- IPO Market Performance: In January 2026, nine IPOs raised a total of $2.6 billion, reflecting a cautious market sentiment as this figure fell short of the ten-year average, particularly after the volatility experienced in Q4 2025.
- Sector Dynamics: The industrial sector led the month’s largest IPOs, with EquipmentShare.com raising $747 million, highlighting investor preference for fast-growing companies perceived as resilient to AI disruption.
- Emerging Trends: The fintech and biotech sectors showed signs of recovery at the start of 2026, notably with fintech PicPay becoming the first Brazilian IPO in four years, raising $434 million, although its shares fell 5% post-IPO.
- SPAC Activity: January saw SPAC issuance reach a four-year high with 25 deals raising $5.2 billion, indicating growing interest in pre-IPO companies opting for SPAC mergers, despite overall IPO activity remaining below 2021 peaks.
See More
Wall Street Analysts Adjust Ratings
- Rating Changes Overview: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market perspectives and expectations for these companies.
- Market Impact Analysis: The changes in analysts' ratings could influence investor decisions, particularly for those considering buying GLIBK stock, as these adjustments convey important market signals.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing a comprehensive market perspective and data support.
- Investment Advice Reminder: Benzinga emphasizes that it does not provide investment advice, urging investors to carefully consider analysts' ratings and market dynamics before making decisions.
See More
Helen Kim Acquires 835,000 Shares of AKTS for $15.03M Investment
- Large Transaction: Helen Susan Kim purchased 835,000 shares of AKTS on Monday at $18 each, totaling a $15.03 million investment, marking her first stock purchase in the past 12 months and indicating confidence in the company's future prospects.
- Price Fluctuation: On Tuesday, AKTS reached a high of $23.50, with Kim's investment up approximately 30.6% at the peak, reflecting a positive market response that may attract further investor interest.
- Market Performance: Aktis Oncology Inc saw a 1.8% increase in stock price on Tuesday, indicating a favorable market reaction to Kim's purchase, which could further stabilize the company's stock growth.
- Another Transaction: On the same day, Carl J. Rickertsen bought 5,000 shares of Strategy at $155.88 each, totaling $779,395, marking his first purchase in the past 12 months and demonstrating optimism towards the company.
See More
Aktis Oncology Closes Upsized IPO Raising $365.4 Million
- Successful IPO: Aktis Oncology completed its initial public offering of 17.65 million shares on January 12, 2026, at an IPO price of $18 per share, indicating strong market demand for its targeted radiopharmaceuticals.
- Additional Share Purchase: Underwriters fully exercised their option to purchase an additional 2.6475 million shares, expected to close on January 14, 2026, further strengthening the company's financial position to support R&D and market expansion.
- Significant Fundraising: The total gross proceeds from the offering are expected to reach approximately $365.4 million, reflecting investor confidence in Aktis's innovative potential in cancer treatment and providing ample funding for future product development.
- Strong Market Debut: Aktis's stock began trading on the Nasdaq Global Select Market on January 9, 2026, under the ticker symbol “AKTS,” marking a successful entry into the capital markets and likely enhancing its brand visibility and competitive position.
See More
